Royal Navy's £1.3bn 'hunter-killer' submarine ready after secret tests at US Navy's 'Area 51'
HMS Anson is the fifth and most advanced in the Royal Navy's Astute-class of nuclear-powered submarines, which can circumnavigate the globe completely submerged beneath the waves
The Royal Navy is preparing to deploy its £1.3billion 'hunter-killer' submarine, the HMS Anson, following weapons tests in the Atlantic and a visit to the US's maritime equivalent of 'Area 51'.
The HMS Anson is the latest addition to the Navy's Astute-class of nuclear-powered vessels, which are capable of circumnavigating the globe completely submerged, making it the most advanced yet.
This formidable vessel can launch long-range Tomahawk missiles to strike land targets as well as Spearfish torpedoes to combat enemy submarines, making the Astute-class the largest in the underwater fleet.
HMS Anson has undergone trials off the east coast of the United States and in the Caribbean Sea, testing these capabilities alongside her state-of-the-art systems.
Anson joins her operational sisters: Astute, Ambush, Artful and Audacious in this impressive class, reports the Express.
Before being officially deployed on military operations, the sub will undergo further rigorous tests. Since leaving its shipyard in Barrow-in-Furness in February 2024, Anson has patrolled the UK coastline before sailing further north of Scotland to test her weapons systems.
The Royal Navy describes these drills as consisting of "successful firings of both Spearfish and Tomahawk test missiles" before matters "intensified into the Atlantic as Anson headed to the Atlantic Undersea Test and Evaluation Center (AUTEC) in the waters around the Bahamas."
AUTEC, nestled beside the Tongue of the Ocean's natural marvel—a vast deep-water basin hewn from coral reef—attracts top military tech experts from around the globe.
The facility has earned a reputation as the US Navy's 'Area 51' due to the classified nature of its operations, and it even featured on History Channel's TV show UFO Hunters, where it was touted as a secret alien underwater base.
In truth, the base spans 20 miles in width, stretches 150 miles in length, plunges up to 6,000ft deep in certain areas, and is packed with sophisticated recording gear to collect data on submarines, torpedoes, and sonar.
While the precise outcomes of Anson's trials remain under wraps, the submarine must perform exceptionally well to confirm her capability to track enemy subs undetected. However, it wasn't all about the grind for her crew.
"The opportunity for the majority of the Ship's Company to get to spend a few days on Andros was fantastic," shared one submariner, recounting the experience.
He added, "This afforded us a few days of rest from the sea trials we were conducting and allowed us to spend time on the beach in the sun, relaxing and playing volleyball with base personnel."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
13 hours ago
- Daily Mirror
New "revolutionary" cancer blood test being rolled out on NHS
The new "liquid biopsy" test searches for tiny fragments of DNA that are shed by tumours into the bloodstream - it can deliver a specific diagnosis up to two weeks earlier than usual tissue biopsy methods A "revolutionary" cancer blood test is set to transform the NHS, marking a global first that promises to fast-track personalised treatment for thousands. The innovative "liquid biopsy" test hunts for minuscule DNA fragments released into the bloodstream by tumours. It boasts the ability to pinpoint a diagnosis up to a fortnight earlier than traditional tissue biopsies, enabling quicker selection of appropriate therapies and reducing the need for superfluous tests and treatments. On the cusp of the world's largest cancer conference in Chicago starting Friday, NHS national clinical director for cancer Professor Peter Johnson proclaimed the dawn of "a new era of personalised cancer care". He suggested that liquid biopsies might one day be used to "scan the body" for emerging cancers with just a single blood draw. Prof Johnson enthused: "It's fantastic that we are now able to expand the use of this revolutionary test on the NHS to help tailor treatment for thousands of patients across the country. "Cutting-edge genomic testing is helping us deliver more targeted and kinder care for patients, enabling some to avoid more intensive treatments such as further chemotherapy, which can have a huge impact.", reports the Express. Following triumphant pilot schemes, the test is poised for deployment across all English hospitals, potentially benefiting up to 15,000 patients annually who are suspected of having non-small cell lung cancer. Individuals will now be given the chance to undergo a test in hospital once their GP or specialist consultant has flagged potential concerns, specifically if a CT scan indicates possible lung cancer. Until recently, tissue biopsies were the norm for confirming diagnoses, with samples then being examined for genomic insights. This innovative approach positions the NHS as the pioneering health system globally to adopt a "blood test first" protocol, relegating tissue biopsies to secondary status. Findings from pilot studies indicate that individuals subjected to this avant-garde testing had expedited access to personalised treatment, syncing with the genetic intricacies of their tumours, roughly two weeks in advance. Additionally, nearly 5,000 women with advanced breast cancer will experience the benefits of this test to ascertain whether they possess one of four genetic variants amenable to new life-prolonging therapies after previous regimens have fallen short. Hospital implementation Implementation has begun in hospitals, rewarding approximately 1,600 patients suspected of having lung cancer and 600 with breast cancer since April. Moreover, the NHS is contemplating the extension of this blood test to other cancer types such as pancreatic and gallbladder. Professor Johnson remarked: "We are already seeing the difference this test can make in lung and breast cancer - and we hope to roll it out for patients with other forms of cancer in the near future. "As research progresses, it's thrilling to think that this method could enable us to 'scan' the body with a single blood test to identify where and in what way cancer may be manifesting and tackle it with rapidity and precision to save more lives." During its pilot phase, approximately 10,000 individuals suffering from non-small cell lung cancer underwent the liquid biopsy across 176 hospitals. An independent assessment of the health economics involved suggests the test might lead to savings of up to £11 million annually in managing lung cancer, by minimising unnecessary diagnostic steps and treatments, including chemotherapy. Professor Sanjay Popat, a consultant medical oncologist at The Royal Marsden and joint clinical head of the pilot scheme, commented: "We have seen first-hand how the implementation of a simple blood-draw and testing in our laboratory has revolutionised treatment for lung cancer patients. "Earlier access to highly effective targeted medicines allows more patients to avoid delays, start treatment early, and start the best treatment for their type of cancer. I am really pleased that we are now able to roll this out nationally." Adding to the enthusiasm, Co-lead Professor Alastair Greystoke, an honorary medical oncologist at the Newcastle upon Tyne Hospitals NHS Foundation Trust, stated: "This is the first ever national implementation of a 'liquid biopsy first' approach to the diagnosis and treatment of a cancer." New method The introduction of a new diagnostic method has not only expedited and refined treatment for lung cancer patients but has also proven to be cost-effective for the NHS, paving the way for its evaluation in other cancers. Professor Dame Sue Hill, Chief Scientific Officer for England, hailed the development as "a real step-change in care for eligible lung and breast cancer patients on the NHS". She further explained: "The liquid biopsy testing enables genomic mutations in the fragments of cancer that enter the bloodstream of these patients to be detected. "This testing is transforming care and helping clinicians match patients earlier especially when cancer tissue may not be available with potentially life-extending targeted therapies rapidly and with greater precision. "This test is a great example of the NHS harnessing the power of genomic technological advances to enable the latest groundbreaking treatment to be delivered to patients." Upcoming research on the application of liquid biopsies for cancer diagnosis and monitoring will be showcased at the American Society for Clinical Oncology's annual conference this weekend. Dr Julie Gralow, ASCO's chief medical officer and executive vice president, commented on the innovation, saying the tests were "a cool way of not having to stick needles into wherever the cancer is, but just drawing blood". She explained, "If you had three spots in the liver, five spots in the bone and a spot in the lung, it might be that 90 per cent of them are still responding to treatment but one is growing. "You can't go and stick a needle in all of them but, if you look in the blood, the most active cancer - the one that's growing - is the one that's shedding its DNA and that's what you're going to find in the blood. It helps you hone in on the active part of the cancer." Revolutionary blood tests Dr Gralow discussed how cancer blood tests could revolutionise the way doctors detect tumour growth and resistance to treatment. She stated, "You can see this mutation happening and intervene before you see obvious evidence of the tumour growing or spreading to new places. "It's live monitoring at a level that is actually much more specific and early than waiting for it to show up on scans." Highlighting the significance of these advancements, Dr Isaac Garcia-Murillas from The Institute of Cancer Research in London called the potential patient benefits and NHS cost savings "incredible". He confirmed that some tests might detect cancer with "micro metastases" far earlier than traditional scans—possibly up to a year sooner. Emphasising the current limitations, he said, "Not only is the whole imaging pathway cumbersome, but by the time you have tested a tumour by imaging it has already grown." Catching cancer at an early stage allows for more timely intervention, and smaller tumours may respond better to treatment which can not only simplify the process but also enhance patient outcomes, according to insights from the medical community. These blood tests have yet to replace tissue biopsies completely, but Dr Garcia-Murillas believes their potential is undeniable. He is excited about the progress, declaring: "I think we are at a stage where something we have researched for years will become the standard of care for most solid tumour types and that is super cool." Sharing her personal success story as testament to the breakthrough, Rebeca explained how the test identified her cancer's ALK genetic mutation, enabling her to start targeted treatment with brigatinib – the presence of the mutation was later confirmed by a tissue biopsy. Emotional toll Reeling from her stage four cancer diagnosis, Rebeca, 41, recounted the emotional toll: "When I found out I had stage four cancer it felt like I'd been punched in the gut." The situation had her thinking of her children's futures anxiously: "I was scared, I just thought about my children, and if I would get to see my little girl start nursery, and how I would explain my diagnosis to my children - it was just heart-breaking to think about." However, she added that the medication had significantly improved her life, remarking: "But the medication has given me my life back and my kids have got their mum back." Rebeca, hailing from Carlisle, had initially been diagnosed and treated for what was thought to be a chest infection, presenting symptoms such as breathlessness, shoulder pain, lethargy, and coughing up blood. She shared an update on her condition: "I'm taking it day-by-day and for now the treatment is doing what it's meant to be doing and shrinking the tumour, and I've got my energy back." Expressing acceptance of her situation, she said, "I know I'm not going to be cured but I've come to terms with my diagnosis and the pills are stopping my cancer cells from spreading. We'll keep fighting this and dealing with what's been thrown at us."
Daily Mirror
a day ago
- Daily Mirror
'Disturbing' 2,000-year-old dolls discovered on top of pyramid by archaeologists
The discovery of the Bolinas figurines, a type of puppet-like artefact, could provide new insights into an ancient society A pair of intrepid archaeologists from the University of Warsaw made a groundbreaking discovery at the San Isidro site in El Salvador - five ancient clay figurines perched atop a dilapidated pyramid. This find, detailed in the journal Antiquity, features rare Bolinas artefacts, akin to puppet-like curios, which are incredibly scarce and were previously unearthed at the early Maya Tak'alik Ab'aj in Guatemala. The figurines date back over two millennia and offer tantalising prospects for shedding light on an olden Mesoamerican civilisation. Carbon-14 analyses confirmed that these pieces hail from between 410 and 380 B.C.E. These recently unearthed treasures, with mouths agape and ranging from mere inches to a sizeable foot in height, possess an interesting design. The larger ones even have removable heads with apertures suited for strings at their necks and craniums. Theorising upon their usage, scientists surmise that inserting string through these openings would allow the figures to be animated, much like rudimentary marionettes, reports the Express. Jan Szymaski revealed his impressions of these historical icons in an interview with ScienceLink's Lizzie Wade, saying: "They are clay actors. When you hold them in your hand, sometimes they even look creepy because of their vivid expressions. "Very little is known about the identities and ethnolinguistic affiliations of the creators of ancient settlements that predate the arrival of Europeans in the early 16th century. This gets worse the further back in time we look. This finding is only the second such a group found in situ, and the first to feature a male figure." El Salvador's pre-Columbian past remains shrouded in mystery, especially when contrasted with its Central American neighbours. The country's dense population coupled with countless years of volcanic activity have obscured and even destroyed many potential archaeological sites. It has been found that artefacts resembling those at San Isidro were also uncovered in parts of Guatemala and other areas in El Salvador as well as Nicaragua, Panama, and Costa Rica; this indicates a possible network between the inhabitants of San Isidro and distant cultures. The site of San Isidro consists mainly of clay formations, built by an unknown civilisation, and has not yet been fully investigated. Researchers stumbled upon the Bolinas figurines amid the remains at the peak of the site's biggest pyramid-shaped structure. Researchers are now hypothesising that these versatile Bolinas figurines could've had a significant role in "rituals that would involve recreation of some actual events or mythical events," as explained by Szymaski in a conversation with Benjamin Taub from IFL Science. Szymaski added: "This discovery contradicts the prevailing notion about El Salvador's cultural backwardness or isolation in ancient times, "It reveals the existence of vibrant and far-reaching communities capable of exchanging ideas with remarkably distant places."
The Independent
7 days ago
- The Independent
Lost WWI submarine captured in never-before-seen images off the California coast
A World War I submarine wreck off the coast of Southern California has been captured for the first time in new video and images made possible using advanced deep-sea imaging technology. The sunken U.S. Navy vessel now resting on the San Diego seafloor is known as the USS F-1. F-class submarines were based in the Pacific, serving at Hawaii and off California. The F-1 was lost at sea following an accidental collision on December 17, 1917, resulting in the death of 19 crew members. While others were rescued, the submarine sank in just 10 seconds. It was found again nearly 60 years later, according to the Submarine Force Library and Museum Association. The high-definition images of the over a century-old submarine were taken in February and March, when researchers at the Massachusetts-based Woods Hole Oceanographic Institution used a human-occupied vehicle called 'Alvin' and the autonomous underwater vehicle named 'Sentry' to travel down 1,300 feet below the surface of the Pacific waters. 'Once we identified the wreck and determined it was safe to dive, we were able to capture never-before-seen perspectives of the sub,' WHOI's Bruce Strickrott, manager of the Alvin Group at WHOI and the sub's senior pilot, said in a statement. 'As a U.S. Navy veteran, it was a profound honor to visit the wreck of the F-1 with our ONR and NHHC colleagues aboard Alvin.' The mission also included team members from the Navy, the Naval History and Heritage Command, and the National Science Foundation. The National Science Foundation completed surveys of the submarine using video cameras, imaging systems on Alvin, as well as sonar systems on Sentry and the research vessel Atlantis. They also examined a Navy torpedo bomber training aircraft that crashed near the same location in 1950. The sonar on Atlantic and Sentry was used to produce maps of the wreck and seafloor, while Alvin's cameras captured images of the wreck that was stitched into models capable of measuring the sub and the marine life it now supports. Researchers were also able to reconstruct the F-1 and create a three-dimensional model. The dives were part of a previously planned training and engineering mission to give pilots-in-training time to hone their skills and to allow for the development of new technology. 'While these depths were well within the dive capability for Alvin and Sentry, they were technical dives requiring specialized expertise and equipment,' Anna Michel, the co-lead of the expedition, said. 'We were careful and methodical in surveying these historical sites so that we could share these stunning images, while also maintaining the reverence these sites deserve.' Following the dives, they held a remembrance ceremony on Atlantic, ringing a bell for each of the service members lost at sea. 'History and archaeology are all about people and we felt it was important to read their names aloud," said Naval History and Heritage Command Underwater Archaeologist Brad Krueger. It was his first in-person dive on a historical wreck site. "The Navy has a solemn responsibility to ensure the legacies of its lost Sailors are remembered.'
